Biovica International AB (publ) (BIOVIC_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

to the Bajvika Q3 interim report. Today, me, Anders Rylander, the CEO of Bajvika, and our CFO, Anders Morén, will be the presenters, and the agenda will be a short introduction about Bajvika, our company. We'll go through the Q3 highlights, Anders will go through the financials and we'll finish off with a summary from me and we'll open up for a Q&A session. During the Q&A session, we will invite our analysts to the call to ask questions, but we will also take questions from the chat using the chat function in the event. And don't forget to check the anonymous checkbox if you want to remain anonymous. Let's go into a short introduction of BioVica. BioVica was founded to commercialize our product DIVITUM. DIVITUM stands for dividing tumor, which indicates what we are measuring. We measure cell proliferation. And as you all know, cell proliferation is what's essential within cancer. That's the way cancer grows. And by measuring cell proliferation, you will get many benefits. You get an indication before start of treatment, how aggressive the disease is. But also it has proven to be an excellent way of monitoring certain targeted treatments within cancer. and be able to provide quick feedback earlier than with the standard methods being used, which is today's image diagnostics, several months ahead of imaging. This is, of course, most important for the patient getting feedback so that the necessary treatment decisions can be made, making the treatment as optimal as possible for the patient. but also for the healthcare providers and the payers, because these treatments within the metastatic area, for example, breast cancer, where we currently have our focus, are priced at $15,000 to $17,000 per patient list price. So being able to spend money where you get efficacy is, of...